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Extraintestinal manifestations are common in Crohn’s disease (CD), with an 
incidence of 22%–44%, and its clinical spectrum is very extensive.1 Metastatic 
Crohn’s disease (MCD) is one of the most uncommon cutaneous extraintestinal 
manifestations.2 It is a rare granulomatous inflammatory process, similar to the 
pathogenic mechanism of CD that occurs in sites discontiguous from the 
gastrointestinal tract.1,3,4 The face is the second rarest location.2,4 
The diagnosis can be confirmed by a histopathological examination which 
characteristically shows sterile, noncaseating granulomas composed of 
Langerhans giant cells, epithelioid histiocytes, lymphocytes, and occasional 
plasma cells, localized to the superficial papillary and deep reticular dermis.3,4  
MCD should be managed in close collaboration with a dermatologist2. First-line 
recommendations include topical steroids or topical tacrolimus, followed by oral 
metronidazole, and if they are still symptomatic, prednisolone 30 mg/d can be 
initiated. Immunomodulators can be considered for treatment-resistant disease. 
Finally, case reports have shown success with tumor necrosis factor-alpha 
inhibitors.1  
A 40-year-old male atient with a 10-year history of Crohn's disease, only with 
jejunal involvement, under infliximab 5mg/kg every eight weeks, in clinical and 
endoscopic remission, started to complain about symmetrical peripheral 
polyarthralgias (wrists, ankles and elbows) that began one month after infliximab 
and resolved immediately after its administration. There was a need to shorten 
infliximab administrations to every six weeks and, after a Rheumatology 
evaluation, oral and topical steroids were associated, with no response. So, it 
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Three months later, progressive dermatological alterations have appeared: 
erythematous plaques on the elbows suggestive of psoriasis and exuberant 
scaling rash on the face (more exuberant on malar and forehead locations) 
(Figure 1A) that was biopsied and which histology revealed interstitial 
granulomatous dermatitis. Multidisciplinary evaluation concluded that it was 
psoriatic arthritis and Metastatic Cutaneous Crohn's Disease of the face. It was 
decided to stop infliximab and swap to ustekinumab. Now, after two 
administrations, there is no joint complaint and there is a clear regression of the 
dermatological lesions (Figure 1B). 
There are some aspects that makes this an extremely rare case: this disorder is 
more commonly seen in patients with colonic or rectal involvement2,3 and our 
patient has only jejunal involvement. A slight female preponderance had been 
observed in a few studies4 and the age of onset of this entity ranged from 29 to 
39 years in adults – the diagnostic of our patient was made later.4 The malar 
region, the chin, and the perioral area are the most usual locations on the face, 
whereas the temporal region, the forehead, and the submandibular area are the 
most infrequent2 – he had more exuberant rash on malar (most usual) and 
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Figure Legend 
Figure 1 A: Scaling rash on the face. B: Regression of the dermatological lesions 
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